[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201070746A1 - Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами - Google Patents

Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами

Info

Publication number
EA201070746A1
EA201070746A1 EA201070746A EA201070746A EA201070746A1 EA 201070746 A1 EA201070746 A1 EA 201070746A1 EA 201070746 A EA201070746 A EA 201070746A EA 201070746 A EA201070746 A EA 201070746A EA 201070746 A1 EA201070746 A1 EA 201070746A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein active
active ingredient
ingredient
pharmaceutical composition
composition containing
Prior art date
Application number
EA201070746A
Other languages
English (en)
Other versions
EA023107B1 (ru
Inventor
Фарид Беннис
Жан-Жак Серрано
Original Assignee
Фарид Беннис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарид Беннис filed Critical Фарид Беннис
Publication of EA201070746A1 publication Critical patent/EA201070746A1/ru
Publication of EA023107B1 publication Critical patent/EA023107B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к фармацевтическим композициям, содержащим по меньшей мере один белковый активный ингредиент, защищенный от пищеварительных ферментов. Указанные фармацевтические композиции содержат указанный по меньшей мере один белковый активный ингредиент в свободной форме, а также для жидкостей содержат системы, способные их буферизовать при рН больше 4 и меньше или равном 8, или для твердых веществ содержат системы, которые при помещении их в жидкую среду оказывают буферный эффект между рН больше 4 и рН меньше или равном 8.
EA201070746A 2007-12-19 2008-12-18 Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами EA023107B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (2)

Publication Number Publication Date
EA201070746A1 true EA201070746A1 (ru) 2011-02-28
EA023107B1 EA023107B1 (ru) 2016-04-29

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070746A EA023107B1 (ru) 2007-12-19 2008-12-18 Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами

Country Status (19)

Country Link
US (1) US8309123B2 (ru)
EP (1) EP2234598A1 (ru)
JP (1) JP5676272B2 (ru)
KR (2) KR101592609B1 (ru)
CN (1) CN101917967B (ru)
AP (1) AP3573A (ru)
AR (1) AR069847A1 (ru)
AU (1) AU2008345474B2 (ru)
BR (1) BRPI0821373B8 (ru)
CA (1) CA2709899C (ru)
EA (1) EA023107B1 (ru)
FR (1) FR2925333B1 (ru)
HK (1) HK1146386A1 (ru)
IL (1) IL206364A (ru)
MA (1) MA31927B1 (ru)
MX (1) MX2010006927A (ru)
TN (1) TN2010000290A1 (ru)
TW (1) TWI461226B (ru)
WO (1) WO2009083686A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094632A1 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation Method for administration of insulin and pharmaceutical composition thereof
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
PL3137060T5 (pl) 2014-05-01 2024-04-08 Sun Pharmaceutical Industries Ltd Kompozycje zawiesinowe o przedłużonym uwalnianiu
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2017001332A (es) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Envase con camara.doble.
CN107205928B (zh) * 2014-11-04 2021-05-11 因华生技制药股份有限公司 不稳定或难溶药物的口服投予
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
FR3120189A1 (fr) * 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) * 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996006632A1 (en) * 1994-09-01 1996-03-07 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
ES2173679T3 (es) * 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2005113008A1 (en) * 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
PT2626368T (pt) * 2004-07-19 2017-03-10 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
WO2006017541A2 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
AU2006249480A1 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
CA2621641C (en) * 2005-09-15 2014-10-21 Council Of Scientific And Industrial Research Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
IL206364A (en) 2016-12-29
WO2009083686A9 (fr) 2009-10-15
WO2009083686A1 (fr) 2009-07-09
CN101917967A (zh) 2010-12-15
AU2008345474B2 (en) 2014-07-31
IL206364A0 (en) 2010-12-30
JP5676272B2 (ja) 2015-02-25
CA2709899A1 (fr) 2009-07-09
TN2010000290A1 (fr) 2011-11-11
CN101917967B (zh) 2013-05-22
EP2234598A1 (fr) 2010-10-06
KR20100095449A (ko) 2010-08-30
BRPI0821373B1 (pt) 2020-04-22
TWI461226B (zh) 2014-11-21
MA31927B1 (fr) 2010-12-01
FR2925333B1 (fr) 2012-04-13
MX2010006927A (es) 2010-12-06
AU2008345474A1 (en) 2009-07-09
BRPI0821373A2 (pt) 2015-06-16
BRPI0821373B8 (pt) 2021-05-25
KR20150132887A (ko) 2015-11-26
CA2709899C (fr) 2018-01-16
US20090176691A1 (en) 2009-07-09
HK1146386A1 (en) 2011-06-03
TW200940107A (en) 2009-10-01
AP3573A (en) 2016-02-08
JP2011506587A (ja) 2011-03-03
AP2010005298A0 (en) 2010-06-30
AR069847A1 (es) 2010-02-24
KR101592609B1 (ko) 2016-02-05
EA023107B1 (ru) 2016-04-29
US8309123B2 (en) 2012-11-13
FR2925333A1 (fr) 2009-06-26

Similar Documents

Publication Publication Date Title
EA201070746A1 (ru) Фармацевтическая композиция, содержащая по меньшей мере один белковый активный ингредиент, защищенный от расщепления ферментами
TR200801337T1 (tr) Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
MA30923B1 (fr) Composes et compositions inhibant la proteine kinase
WO2008016490A3 (en) Modified two-component gelation systems for the treatment of post-myocardial infarction
DOP2011000074A (es) Compuestos y composiciones como inhibidores de proteina cinasa
WO2008036932A3 (en) Compositions and methods comprising boswellia species
UA91815C2 (ru) Выделенное антитело, которое специфически связывает gdf-8, и его применение
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
EA200802135A1 (ru) Фармацевтические композиции антагонистического антитела к cd40
WO2007056228A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2009102367A3 (en) Tight junction protein modulators and uses thereof
WO2008112368A3 (en) Phenylalkylcarboxylic acid delivery agents
WO2008021250A3 (en) Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
NO20065791L (no) Asyklovir-formuleringer
WO2005113514A3 (en) Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems
WO2006008401A3 (fr) Composition comprenant un milieu de culture de microorganisme marin et/ou d'eau douce photosynthetique.
WO2009061491A3 (en) Type iii secretion inhibitors and uses thereof
ITRM20050064A1 (it) Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
TH127197A (th) องค์ประกอบทางเภสัชกรรมที่มีตัวยาสำคัญของโปรตีนอย่างน้อย 1 ชนิด ที่ถูกปกป้องจากเอ็นไซม์ที่ใช้ในการย่อย
FR2909984B1 (fr) Silo pour le stockage de produits en vrac, notamment des boues sechees de stations d'epuration.
WO2008140577A3 (en) Cd44 pathway antagonists for treatment of adenoviral infection